Logo

PhoreMost, Wistar Institute to Collaborate on Novel Drug Target Discovery

Mar 10, 2016 | staff reporter

NEW YORK (GenomeWeb) – PhoreMost announced today that it has formed a collaboration with The Wistar Institute to identify novel drug targets in cancer, aging, and immune disorders.

Under the terms of the arrangement, Wistar scientists will develop high-throughput phenotypic assays for currently undruggable disease targets. PhoreMost will use its Siteseeker live-cell phenotypic screening platform to find points of possible therapeutic intervention for these targets, then develop small molecules against them.

Wistar will also provide specialist disease biology knowledge and drug mode-of-action studies on a project-by-project basis to support PhoreMost's drug-discovery efforts.

Additional terms were not disclosed.

Filed under

Cancer
Drug Discovery & Development
Business News
aging
immune system diseases
Wistar Institute
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.